AU2013372004B2 - Human serum albumin binding compounds and fusion proteins thereof - Google Patents

Human serum albumin binding compounds and fusion proteins thereof Download PDF

Info

Publication number
AU2013372004B2
AU2013372004B2 AU2013372004A AU2013372004A AU2013372004B2 AU 2013372004 B2 AU2013372004 B2 AU 2013372004B2 AU 2013372004 A AU2013372004 A AU 2013372004A AU 2013372004 A AU2013372004 A AU 2013372004A AU 2013372004 B2 AU2013372004 B2 AU 2013372004B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
polypeptide
serum albumin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013372004A
Other languages
English (en)
Other versions
AU2013372004A1 (en
Inventor
Isabella Attinger-Toller
Julian Bertschinger
Fabian Buller
Dragan Grabulovski
Patricia Henne
Susann Konig-Friedrich
Ulrike Von Der Bey
Ulrich Wullner
Irene Zbinden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of AU2013372004A1 publication Critical patent/AU2013372004A1/en
Application granted granted Critical
Publication of AU2013372004B2 publication Critical patent/AU2013372004B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013372004A 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof Ceased AU2013372004B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13150171.0 2013-01-03
EP13150171.0A EP2752426A1 (en) 2013-01-03 2013-01-03 Human serum albumin binding compounds and fusion proteins thereof
PCT/EP2013/077227 WO2014106583A1 (en) 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof

Publications (2)

Publication Number Publication Date
AU2013372004A1 AU2013372004A1 (en) 2015-07-16
AU2013372004B2 true AU2013372004B2 (en) 2017-05-25

Family

ID=47458817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013372004A Ceased AU2013372004B2 (en) 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof

Country Status (7)

Country Link
US (2) US9790475B2 (enExample)
EP (2) EP2752426A1 (enExample)
JP (1) JP2016508143A (enExample)
AU (1) AU2013372004B2 (enExample)
CA (1) CA2896962A1 (enExample)
HK (1) HK1215441A1 (enExample)
WO (1) WO2014106583A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018220516B2 (en) 2017-02-16 2025-03-06 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
CN107353346A (zh) * 2017-08-09 2017-11-17 芜湖英特菲尔生物制品产业研究院有限公司 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
CA3170750A1 (en) * 2020-03-06 2021-09-10 Yi Shi Serum albumin binding nanobody compositions and methods for using the same
CN116284373A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
MX354717B (es) * 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase

Also Published As

Publication number Publication date
AU2013372004A1 (en) 2015-07-16
HK1215441A1 (zh) 2016-08-26
JP2016508143A (ja) 2016-03-17
US20190169581A1 (en) 2019-06-06
EP2941439B1 (en) 2018-01-31
CA2896962A1 (en) 2014-07-10
US20160076011A1 (en) 2016-03-17
WO2014106583A1 (en) 2014-07-10
EP2941439A1 (en) 2015-11-11
EP2752426A1 (en) 2014-07-09
US9790475B2 (en) 2017-10-17
US10364419B2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
US10364419B2 (en) Human serum albumin binding compounds and fusion proteins thereof
US20210198380A1 (en) Anti-cancer fusion polypeptide
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
EP3896083B1 (en) Fc fusion proteins comprising novel linkers or arrangements
AU2014256037B2 (en) Novel bispecific binding molecules with antitumoral activity
US12331090B2 (en) Multispecific proteins
JP2015528003A (ja) 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体
CA2790329A1 (en) Fibronectin based scaffold domain proteins that bind il-23
JP6840907B2 (ja) ＦＧＦＲ３結合分子ｌｋｏｋｏｋ
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired